SKK
TEVA icon

Shepherd Kaplan Krochuk’s Teva Pharmaceuticals TEVA Stock Holding History

Shepherd Kaplan Krochuk’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-10,600
Closed -$352K – 242
2017
Q2 		$352K Buy
+10,600
New +$328K 0.21% 110
2017
Q1 		– Sell
-21,100
Closed -$765K – 282
2016
Q4 		$765K Sell
21,100
-20,500
-49% -$818K 0.22% 59
2016
Q3 		$1.91M Hold
41,600
– – 0.4% 35
2016
Q2 		$2.09M Hold
41,600
– – 0.52% 34
2016
Q1 		$2.23M Sell
41,600
-82,400
-66% -$4.83M 0.69% 31
2015
Q4 		$8.14M Buy
+124,000
New +$7.66M 2.15% 13

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Shepherd Kaplan Krochuk's TEVA Position: Q2 2017 in Review

Shepherd Kaplan Krochuk sold out of Teva Pharmaceuticals (TEVA) in Q2 2017, closing a stake of 10,600 shares — an estimated $328K sold.

Shepherd Kaplan Krochuk first reported a position in TEVA in Q3 2014 and held it in 3 quarters. The position peaked at $340K in Q1 2017. 648 funds tracked by Wall St. Rank hold TEVA as of Q2 2017.

  • Shepherd Kaplan Krochuk reported no remaining Teva Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Shepherd Kaplan Krochuk sold 10,600 Teva Pharmaceuticals shares in Q2 2017, an estimated $328K.
  • Shepherd Kaplan Krochuk first reported a position in Teva Pharmaceuticals in Q3 2014 and held it in 3 quarters.
  • Shepherd Kaplan Krochuk's Teva Pharmaceuticals position peaked at $340K in Q1 2017.
  • 648 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2017.

Based on Shepherd Kaplan Krochuk's 13F filing for Q2 2017, filed 10 Aug 2017.